Loading viewer...
investor_presentation
Format: PDF investor_presentation
INMB presents two clinical platforms targeting CNS and oncology. XPro treats Alzheimer's as an immunologic disease without immunosuppression, while INKmune creates memory-like NK cells for solid tumors. Phase 2 Alzheimer's data expected early 2025 and Phase 1 metastatic prostate cancer results anticipated late 2024.
investor_presentation
40 Pages
Spar Nord
Australian Strategic Materials 2020 Investor Presentation | Critical Metals
investor_presentationinvestor_presentation
14 Pages
Australian Strategic Materials Limited